Compounds and methods for treating cancer
US-2020061055-A1 · Feb 27, 2020 · US
US11325892B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11325892-B2 |
| Application number | US-201916422519-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 24, 2019 |
| Priority date | Aug 7, 2014 |
| Publication date | May 10, 2022 |
| Grant date | May 10, 2022 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
This document provides compounds, compositions, and methods for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, compounds, compositions, and methods for using one or more inhibitors of SCD1 to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)), thyroid cancer, or liver cancer; or to increase the efficacy of treatment for the same.
Opening claim text (preview).
What is claimed is: 1. A compound according to Formula (II): or a pharmaceutically acceptable salt thereof, wherein R 1 is halo; X is —(C═O)NR 4 —; Y is and R 2 , R 3 , and R 4 are each independently H or an unsubstituted C 1-6 alkyl. 2. The compound of claim 1 , wherein the compound according to Formula (II) has the structure of Formula (IIa): or a pharmaceutically acceptable salt thereof. 3. The compound of claim 1 , wherein R 1 is Cl. 4. The compound of claim 1 , wherein R 4 is H. 5. The compound of claim 1 , wherein R 2 is H and R 3 is CH 3 . 6. The compound of claim 1 , wherein the compound according to Formula (II) is or a pharmaceutically acceptable salt thereof. 7. A pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt thereof, according to claim 1 , and a pharmaceutically acceptable carrier.
attached in position 2 or 6 · CPC title
Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin · CPC title
having a hetero atom as the second substituent in position 4 · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
from aromatic carboxylic acids · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.